Bioverativ, A Sanofi Company

This phase 2 study tested a drug called SAR445088 in 98 adults with CIDP, a nerve disorder causing weakness and numbness. The trial looked at how well the drug works in people who are on standard treatment, those who don't respond to it, and those who haven't tried it yet. Resear…

This early-stage trial tested a single injection of a new drug called BIVV001 in 6 adults with severe forms of von Willebrand disease (types 2N and 3). The goal was to see how the drug behaves in the body and whether it is safe. If results are promising, larger studies could foll…

This early-stage trial tested a single dose of the drug BIVV020 in 12 adults with cold agglutinin disease, a rare condition where the immune system mistakenly attacks red blood cells. The main goal was to see if the drug is safe and tolerable. Researchers also looked at how it af…

This phase 3 study tested a new medicine called BIVV001 (efanesoctocog alfa) in 159 people aged 12 and older with severe hemophilia A. The goal was to see if regular injections could prevent bleeding episodes, improve joint health, and enhance quality of life. Participants receiv…

This study tested a new drug called BIVV001 in 74 children under 12 with severe hemophilia A, a condition where blood doesn't clot properly. The drug is given through a vein and aims to prevent bleeding episodes. The trial found that the drug was safe and effective at reducing bl…

This phase 2a trial tested the drug BIVV020 in 12 adults with persistent or chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, raising bleeding risk. The main goal was to see if BIVV020 could help maintain a safe platelet count over tim…